» Articles » PMID: 10862029

Genetics of Uterine Leiomyomata

Overview
Date 2000 Jun 22
PMID 10862029
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Leiomyomata represent the most common gynecologic tumors in women of reproductive age and are the primary indication for hysterectomy in the United States. Cytogenetic and genetic studies have in recent years advanced our understanding of the etiology of these tumors. Cytogenetic aberrations involving chromosomes 6, 7, 12, and 14 constitute the major chromosomal abnormalities seen in leiomyomata and have led to the discovery that disruptions or dysregulations of HMGIC and HMGIY contribute to the development of these tumors. Based on the finding of a variety of other consistent chromosomal aberrations detected in these tumors, other genes with fundamental roles in the pathobiology of uterine leiomyomata await identification. Genes Chromosomes Cancer 28:235-245, 2000.

Citing Articles

Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.

Chang H, Dermawan J, Sharma A, Dickson B, Turashvili G, Torrence D Mod Pathol. 2023; 37(2):100402.

PMID: 38141829 PMC: 11251009. DOI: 10.1016/j.modpat.2023.100402.


Benign Metastasizing Leiomyomatosis to the Skin and Lungs, Intravenous Leiomyomatosis, and Leiomyomatosis Peritonealis Disseminata: A Series of Five Cases.

Boavida Ferreira J, Cabrera R, Santos F, Relva A, Vasques H, Gomes A Oncologist. 2022; 27(1):e89-e98.

PMID: 35305104 PMC: 8842467. DOI: 10.1093/oncolo/oyab019.


Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison.

Koltsova A, Efimova O, Malysheva O, Osinovskaya N, Liehr T, Al-Rikabi A Biomedicines. 2021; 9(12).

PMID: 34944592 PMC: 8698342. DOI: 10.3390/biomedicines9121777.


Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays.

Su L, Bryan N, Battista S, Freitas J, Garabedian A, DAlessio F Sci Rep. 2020; 10(1):18850.

PMID: 33139812 PMC: 7606612. DOI: 10.1038/s41598-020-75890-0.


Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females.

Souftas V, Deuteraiou D, Anthoulaki X, Chalkidou A, Bothou A, Gaidatzi F Exp Ther Med. 2020; 19(6):3684-3690.

PMID: 32346432 PMC: 7185183. DOI: 10.3892/etm.2020.8652.